Yes Dewologist, and that is why I responded to your article as the reference...it is from Nature.com, and hence should be 100% credible, but ahhhhh....
Peace Dewster, and the only thing certain is and was that Wagner would blow the game..haha.
No doubt there's been some great takeouts and they're on the rise. But that's the numerator. What's the denominator of small biotechs with tiny market caps, running short on cash? There's been a few awful reverse mergers, a bankruptcy and a few others where bankruptcy is very likely (gtop, fvrl etc). Not to mention terribly dilutive firesale or worse financings.
Market Data 
Markets 
AI
